CRASH 3: a monumental effort with minimal gain

Affiliations

¹ Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka, 560029, India.
² Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka, 560029, India. nishanth46@gmail.com.

Comment

Chinmay Vilas Phadtare et al. Eur J Trauma Emerg Surg. 2021 Feb.

. 2021 Feb;47(1):269-271.

doi: 10.1007/s00068-020-01424-y. Epub 2020 Jun 24.

¹ Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka, 560029, India.
² Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka, 560029, India. nishanth46@gmail.com.

No abstract available

Comment on

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
CRASH-3 trial collaborators. CRASH-3 trial collaborators. Lancet. 2019 Nov 9;394(10210):1713-1723. doi: 10.1016/S0140-6736(19)32233-0. Epub 2019 Oct 14. Lancet. 2019. PMID: 31623894 Free PMC article. Clinical Trial.
Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial.
CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators. CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators. Eur J Trauma Emerg Surg. 2021 Feb;47(1):261-268. doi: 10.1007/s00068-020-01316-1. Epub 2020 Feb 19. Eur J Trauma Emerg Surg. 2021. PMID: 32076783 Free PMC article. Clinical Trial.

1. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial [published correction appears. Lancet. 2019;394(10210):1713–23. - DOI
1. CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators. Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial. Eur J Trauma Emerg Surg. 2020. https://doi.org/10.1007/s00068-020-01316-1 . - DOI
1. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomized controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patient. Health Technol Assess. 2013;17:1–79. - DOI
1. Sprigg N, Flaherty K, Appleton JP, et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391:2107–15. - DOI
1. Hu W, Xin Y, Chen X, et al. Tranexamic acid in cerebral hemorrhage: a meta-analysis and systematic review. CNS Drugs. 2019;33:327–36. - DOI